Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Efficacy of Zonisamide CR Plus Bupropion SR in Uncomplicated Obesity
NCT00339014Phase 2Completed
- Sponsor
- Orexigen Therapeutics
- Start
- May 2006
- Primary completion
- Aug 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of zonisamide and bupropion in obesity (7 arms), sponsored by Orexigen Therapeutics. Primary endpoint: Percentage Change in Total Body Weight at 24 weeks. Started May 2006; status: completed.
02
Drugs
zonisamidebupropion
03
Conditions
obesity
Beyond the preview
Go deeper on NCT00339014.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00339014.